- 020 3313 8117
Kim Whittington, secretary
Dr Aristeidis Chaidos has been a consultant haematologist and honorary senior lecturer at the Hammersmith Hospital and Imperial College London since 2012, with clinical and research interest in multiple myeloma, lymphomas and haematopoietic stem cell transplantation. He graduated from the University of Ioannina Medical School, Greece in 1995. He completed his training in haematology and PhD research on multiple myeloma at the same institution in 2005. He was then trained in haematopoietic stem cell transplantation at the Hammersmith Hospital (2005–2007) and later he joined Professor Karadimitris’ laboratory for post-doctoral research on multiple myeloma.
Multiple myeloma, lymphoma, stem cell transplantation
Research & publications
Dr Chaidos has a strong research interest in multiple myeloma propagating cells, epigenetic mechanisms of drug resistance and novel therapies. He is a principal investigator and co-investigator in several clinical studies on multiple myeloma and lymphomas. He has published more than 45 articles in peer-reviewed journals.
Chaidos, A., Caputo, V. & Karadimitris, A. (2015) Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence. Therapeutic Advances in Hematology, Jun, 6(3), 128-41. http://www.ncbi.nlm.nih.gov/pubmed/26137204
Chaidos, A., Caputo, V., Marigo, I., Liu, B., Chaudhry, S., Tough, D., Smithers, N., Bassil, A., Chapman, T., Harker, N., Barbash, O., Tummino, P., Al-Mahdi, N., Haynes, A., Cutler, L., Le, B., Rahemtulla, A., Roberts, I., Kleijnen, M., Witherington, J., Parr, N., Prinjha, R. & Karadimitris, A. (2014) Potent in vitro and in vivo anti-myeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762. Blood, Jan 30, 123(5), 697-705. http://www.ncbi.nlm.nih.gov/pubmed/24335499
Chaidos, A., Barnes, C. P., Cowan, G., May, P. C., Melo, V., Hatjiharissi, E., Papaioannou, M., Harrington, H., Doolittle, H., Terpos, E., Dimopoulos, M., Abdalla, S., Yarranton, H., Naresh, K., Foroni, L., Reid, A., Rahemtulla, A., Stumpf, M., Roberts, I. & Karadimitris, A. (2013) Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma. Blood, Jan 10, 121(2), 318-28. http://www.ncbi.nlm.nih.gov/pubmed/23169779
Chaidos, A., Patterson, S., Szydlo, R., Chaudhry, M. S., Dazzi, F, Kanfer, E., McDonald, D., Marin, D., Milojkovic, D., Pavlu, J., Davis, J., Rahemtulla, A., Rezvani, K., Goldman, J., Roberts, I., Apperley, J. & Karadimitris, A. (2012) Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation. Blood, May 24, 119(21), 5030-6. http://www.ncbi.nlm.nih.gov/pubmed/22371885
Investigator in clinical studies:
Phase 2 Study of E7438 (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With B cell Lymphomas (PI)
Phase 3 Randomized, Controlled, Open-label Study of VMP Compared to Daratumumab in Combination with VMP (D VMP), in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Therapy (PI)
Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Citrate (MLN9708) Maintenance Therapy in Patients With Multiple Myeloma Following Autologous Stem Cell Transplant (PI)
Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation (PI)
Phase 1 open-label, dose escalation study to investigate the safety, pharmacokinetics, pharmacodynamics and clinical activity of GSK525762 in subjects with relapsed refractory haematologic malignancies (co-PI)